Latest Content

Melody Chang, RPh, BCOP, MBA, of the American Oncology Network, discusses building outpatient infrastructure for bispecific antibody and CAR-T therapy.

The researchers used efficiency frontier analysis, an alternative to quality-adjusted life years (QALYs), to rank adalimumab, secukinumab and bimekizumab, biologics used for hidradenitis suppurativa.

The Senate confirmed Erica Schwartz, M.D., J.D., M.P.H., 51-44, as CDC director, ending the agency's nearly year-long leadership vacancy.

Tufts researcher James Chambers, Ph.D., says IRA’s Medicare price negotiation program should target drugs that are unlikely to face biosimilar competition.

Journavx acute pain drug sees prescription surge as non-opioid coverage expands, lifting 2026 outlook and pain pipeline.

A mouse study found that formoterol was able to reduce liver fat, and a real-world analysis found that the asthma drug was associated with fewer complications from advanced liver disease and lower rates of several serious liver-related outcomes, including cirrhosis and all-cause mortality.

A South African trial found a doravirine-based HIV regimen caused less weight gain than a dolutegravir-based combination.

In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, discusses how biosimilars have improved access to biologics, but more work needs to be done for patients to see cost reductions.

Genomic testing among Medicare beneficiaries with cancer rose from 6% in 2016 to 16.7% in 2023, though NGS use stayed low, a study found.

Yesafili joins Amgen's Pavblu as a competing Eylea biosimilar.

From her perch at Navitus, Crosson has become a prominent advocate on PBM transparency and prescription drug affordability issues, frequently speaking with policymakers, industry groups, and healthcare stakeholders about legislative reforms and regulatory trends.

The move toward integrating HIV services with other healthcare services was already underway before the PEPFAR cuts, says Warren, executive director of AVAC.

Zambia's infectious disease director says data and specimen sharing, not mineral rights, are what's holding up its still-unsigned U.S. health memorandum of understanding.

Like Journavx, LTG-001 is a Nav1.8 inhibitor that is designed to selectively block the transmission of pain without the risk of addiction.

CMS said its Medicaid Fraud War Room suspended more than $203 million in improper payments and flagged 50 high-risk providers in its first 88 days of operation.

It is not surprising that it is taking some time for injectable lenacapavir for PrEP to catch, an Emory Univeristy researchers say the patterns of use in the early months of lenacapavir's availability are similar to inequities seen with older versions of PrEP.

Children using virtual reality needed significantly lower nitrous oxide concentrations during Botox procedures, potentially reducing side effects like nausea, vomiting, and hallucinations, researchers reported.

CMS has set the 2027 Part D bid amount at $296.05 and will end its premium stabilization demonstration, raising cost questions for 25 million enrollees.

Specialty drug spend is being driven by utilization, while the non-specialty trend is being pushed up as a result of the use of GLP-1s for diabetes and for weight loss.

Lowering the dose of islatravir from 20 milligrams to two seems to have solved problem of sinking CD4+ T cell counts.

Community-led programs across four countries show gains in HIV retention, mental health and service uptake among people who engage in chemsex.

Questions about price and access hover over the positive results for a weekly HIV treatment pill that combines Merck’s islatravir and Gilead’s lenacapavir.

Data presented at the International AIDS Conference 2026 show Cabenuva reduced viral rebound in adolescents versus oral therapy, but access to long-acting injectables remains limited where need is greatest, investigators said.

Raphael J. Landovitz, M.D., of UCLA, says HIV prevention science has surged ahead of the world's ability to deliver it.

Raphael J. Landovitz, M.D., says rare lenacapavir breakthrough infections raise new questions about how often patients need testing between PrEP doses.

Raphael J. Landovitz, M.D., of UCLA says surveillance gaps, Medicaid nonexpansion states and injectable pricing are stalling U.S. PrEP uptake.

Zambia's director of infectious disease spoke about the pared-down "basic minimum package" now adopted in Malawi, Mozambique and Kenya as U.S. funding for HIV response tightened.

Real-world CAPTIVATE study of 241 CAB LA users found no HIV acquisitions, 99% satisfaction and 97% preference over oral PrEP.

Researchers report positive results from open-label extension studies amid looming concerns that the long-acting injectable won’t be available where it is needed.

The lack of a standard, clear approach to present prices to consumers is a big reason why healthcare costs keep rising.

Disbursements for the HIV response dropped by 25% from 2024 to 2025